Two abstracts on Clarity’s diagnostic COBRA and CLARIFY trials with 64Cu-SAR-bisPSMA have been accepted for presentation at the American Society of Clinical Oncology Genitourinary Cancers Symposium ...

SAN DIEGO - Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biotech company currently valued at $171 million, has shared promising clinical data from its studies of azenosertib, a small ...

Results from DENALI Part 1b show an Objective Response Rate (ORR) of ~35% in response-evaluable, heavily-pretreated patients with Cyclin E1+ ...

Pharmaceuticals presented updated azenosertib monotherapy clinical data from its ZN-c3-001, MAMMOTH and DENALI studies and ...

A Peter Mac-led international clinical trial has shown adding an immunotherapy drug to the chemotherapy that patients receive ...

Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the tally of failed drugs in the innovative “Healey platform trial” to seven.

Our mission is to support the development of Clinical Psychology, both as a profession and as a body of knowledge and skills. By working collaboratively with a number of organisations including the ...

Exelixis, Inc. (NASDAQ:EXEL), currently trading near $33, continues to build on the success of its flagship product ...

AstraZeneca has received approval from the FDA for its BTK inhibitor, Calquence (acalabrutinib), for first-line use in MCL.

TG Therapeutics said it is working to develop a subcutaneous (under-the-skin) version of relapsing MS therapy Briumvi.

This executive interview, sponsored by BeiGene, is with Jan-Henrik Terwey, Vice President, Medical Affairs Europe at BeiGene.

During a Case-Based Roundtable® event, Catherine Coombs, MD, discussed the BRUIN trial and recent NCCN updates on chronic ...